Recombinant human interferons

Rosina E, Pintus C, Meschievitz C, Rizzedo M (1991) A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis a multicenter Italian study. Hepatology 13 1052-1056... [Pg.239]

Jaffe, H.S. and Herberman, R.B., Rationale for recombinant human interferon-gamma adjuvant immunotherapy for cancer, J Natl. Cancer Inst., 80, 616, 1988. [Pg.167]

It should be noted that the unfolding kinetics can sometimes involve quite complex unfolding schemes of different substates in equilibrium with the native state. Staphylococcal nuclease is an example of such behavior, known to unfold with three different substates that exhibit an equilibrium that does not appear to shift with temperature.49 Irreversible aggregation processes of proteins have been known to involve first- or second-order reactions.132141 The mechanism of recombinant human interferon-y aggregation is an example where thermodynamic and kinetic aspects of the reaction provided a powerful tool for understanding the pathway of instability and permitted a rationale for screening excipients that inhibited the process.141... [Pg.371]

Kendrick, B.S., J.F. Carpenter, J.L. Cleland, and T.W. Randolph. 1998. A transient expansion of the native state precedes aggregation of recombinant human interferon-gamma. Proc Natl Acad Sci U.S.A. 95 14142-14146. [Pg.382]

High temperatures can break native S-S bonds and form new S-S bonds which can lock the protein into a denatured eonfiguration [89]. Low pH, sodium dodecyl sulfate. Tween 80, chaotropie salts, and exogenous proteins have been used to protect proteins from thermal inaetivation [90]. Ethylene glycol at 30-50% was used to protect the antiviral activity of P-interferon preparations [91]. Human serum albumin was used in recombinant human interferon-Psei-n which resulted in increased thermal stability [62]. Water-soluble polysaeeharides sueh as dextrans and amylose [92], as well as point-specific (site-directed) mutagenesis [93] have also been used to increase thermal stability of therapeutie proteins and peptides. [Pg.212]

Byhardt, R.W., L. Vaickus, PL. Witt, A.Y Chang, T. McAuliffe, J.E. Wilson, C.A. Lawton, J. Breitmeyer, M.E. Alger, and E.C. Borden, Recombinant human interferon-beta (rHuIFN-beta) and radiation therapy for inoperable non-small cell lung cancer. J Interferon Cytokine Res, 1996. 16(11) 891-902. [Pg.175]

Knobler, R.L., J.I. Greenstein, K.P. Johnson, ED. Lublin, H.S. Panitch, K. Conway, S.V. Grant-Gorsen, J. Muldoon, S.G. Marcus, J.C. Wallenberg, et al., Systemic recombinant human interferon-beta treatment of relapsing- remitting multiple sclerosis pilot study analysis and six-year follow-up. J Interferon Res, 1993. 13(5) 333-40. [Pg.175]

Arakawa T, Hsu YR, Parker CG, Lai PH. Role of polycationic C-terminal portion in the structure and activity of recombinant human interferon gamma. J Biol Chem 1986 261 8534-8539. [Pg.455]

Hermeling S, Aranha L, Damen JM, et al. Structural characterization and immunogeni-city in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm Res 2005 22(12) 1997-2006. [Pg.304]

Avonex (interferon beta- Biogen-Idec la) [CHO-expressed glycoprotein-recombinant human interferon beta-la]... [Pg.309]

Beatseron (interferon-beta-lb) [E. coli expressed recombinant human interferon beta] Berlex, Inc. Lyophilized (0.3 mg single-dose vial)... [Pg.310]

Supersaxo, A.,W. Hein, H. Gallati, and H. Steffen. 1988. Recombinant human interferon-a-2a delivery to lymphoid tissue by selected modes of application. Pharm. Res. 5 472-476. [Pg.38]

Curling EM, Hayter PM, Baines AJ, Bull AT, Gull K, Strange PG, Jenkins N (1990), Recombinant human interferon-gamma. Differences in glycosylation and proteolytic processing lead to heterogeneity in batch culture, Biochem. J. 272 333-337. [Pg.143]

Flayter PM, Curling EMA, Baines AJ., Jenkins N, Salmon I, Strange PG, Tong JM, Bull AT (1992), Glucose-limited chemostat culture of Chinese hamster ovary cells producing recombinant human interferon-. Biotechnol. Bioeng. 39 327-335. [Pg.144]

The selection of the type of assay depends on the nature of the biological material available for assay. The bioassays can demonstrate the consistency of the product s biological activity by replicate analysis as well as define the potency of each lot. Figure 13.5 shows the analysis of biological activity of a sample of recombinant human interferon- 3la (rhIFNpia). [Pg.342]

Determination of the in vitro biological activity of rhIFNpl a (recombinant human interferon- 31a). Standard ( ), production sample of rhIFNpla (A). The curves corresponding to the standard and the sample were processed in triplicate and the results are shown as the average value SD. The dotted horizontal lines indicate the average values of the test s negative and positive controls processed in quadruplicate. [Pg.343]

An example where the original species was not relevant is that of the early work performed on the interferons. The studies were performed in nonrelevant species and generated misleading information [7], Several studies were conducted in rodents with recombinant human interferons with little evidence of... [Pg.115]

TerrellTG, Green JD. Comparative pathology of recombinant murine interferon-y in mice and recombinant human interferon-y in cynomolgus monkeys. Exp Pathol 1993 34B 73,101. [Pg.289]

Recombinant human interferon beta-la binds to multiple receptors... [Pg.935]

Ealick, S. E., Cook, W. J., Vijay-Kumar, S., Carson, M., Nagabhushan, T. L., Trotta, P. P., and Bugg, C. E. (1991). Three-dimensional structme of recombinant human interferon-gamma. Science 252, 698-702. [Pg.217]

Bayley et al. 1995(77] Recombinant human interferon-a B/D hybrid (rat, rabbit)... [Pg.2673]

Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d lmmunotherapie. N Engl J Med 1998 338(18) 1272-8. [Pg.66]

Buraglio M, Trinchard-Lugan I, Munafo A, Macnamee M. Recombinant human interferon-beta-la (Rebif) vs recombinant interferon-beta-lb (Betaseron) in healthy volunteers. A pharmacodynamic and tolerability study. Chn Drug Invest 1999 18 27-34. [Pg.1836]

Elgart GW, Sheremata W, Ahn YS. Cutaneous reactions to recombinant human interferon beta-lb the clinical and histologic spectrum. J Am Acad Dermatol 1997 37(4) ... [Pg.1837]

Colosimo C, Pozzilli C, Frontoni M, Farina D, Koudriavtseva T, Gasperini C, Salvetti M, Valesini G. No increase of serum autoantibodies during therapy with recombinant human interferon-betala in relapsing-remitting multiple sclerosis. Acta Neurol Scand 1997 96(6) 372-4. [Pg.1838]

Weening RS, Leitz GJ, Seger RA. Recombinant human interferon-gamma m patients with chronic granulomatous disease—European follow up study. Em J Pediatr 1995 154(4) 295-8. [Pg.1840]

James DC, Freedman RB, Hoare M, Ogonah OW, Rooney BC, Larionov OA, Dobrovolsky VN, Lagutin OV Jenkins N (1995) N-Glycosylation of recombinant human interferon-y produced in... [Pg.14]

James DC, Freedman RB, Hoare M Jenkins N (1994) High resolution separation of recombinant human interferon-gamma glycoforms by unicellar electro-kinetic capillary chromatography. Analytical Biochemistry 222 315-322. [Pg.291]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...